STRUCTURE-ACTIVITY RELATIONS OF ANALOGS OF PHENYLBUTAZONEMOSER P; JAKEL K; KRUPP P et al.1975; EUROP. J. MEDICIN. CHEM.; FR.; DA. 1975; VOL. 10; NO 6; PP. 613-617; ABS. FR. ALLEM.; BIBL. 27 REF.Article

ZUM WIRKUNGSMECHANISMUS VON VOLTAREN = MECANISME D'ACTION DU VOLTARENKRUPP P; EXER B; MENASSE R et al.1976; THERAPIEWOCHE; DTSCH.; DA. 1976; VOL. 26; NO 18; PP. 2877-2890 (6P.); BIBL. 1 P.Article

BIOTRANSFORMATION OF DICLOFENAC SODIUM (VOLTAREN^REG.) IN ANIMALS AND IN MAN. I: ISOLATION AND IDENTIFICATION OF PRINCIPAL METABOLITESSTIERLIN H; FAIGLE JW; SALLMANN A et al.1979; XENOBIOTICA; GBR; DA. 1979; VOL. 9; NO 10; PP. 601-610; BIBL. 16 REF.Article

Synthesis and quantitative structure-activity relationships of diclofenac analoguesMOSER, P; SALLMANN, A; WIESENBERG, I et al.Journal of medicinal chemistry (Print). 1990, Vol 33, Num 9, pp 2358-2368, issn 0022-2623Article

Characterization of a novel diclofenac metabolite in human urine by capillary gas chromatography-negative chemical ionization mass spectrometryBLUM, W; FAIGLE, J. W; PFAAR, U et al.Journal of chromatography. Biomedical applications. 1996, Vol 685, Num 2, pp 251-263, issn 0378-4347Article

Pharmacological properties of five diclofenac metabolites identified in human plasmaWIESENBERG-BOETTSCHER, I; PFEILSCHIFTER, J; SCHWEIZER, A et al.Collection sécurité. 1991, Vol 34, Num 1-2, pp 135-137, issn 0538-4818Conference Paper

Strategies in the design of peptidoleukotriene antagonistsVON SPRECHER, A; BECK, A; GERSPACHER, M et al.Journal of lipid mediators. 1993, Vol 6, Num 1-3, pp 265-273, issn 0921-8319Conference Paper